Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 11/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434617 | 0.98 | GLP1R (0.55) | GLP1R | |
| SCHEMBL29489377 | 0.92 | GLP1R (0.60) | GLP1RIL23R | |
| SCHEMBL30952344 | 0.91 | GLP1R (0.61) | GLP1R | |
| SCHEMBL30434959 | 0.90 | GLP1R (0.57) | GLP1RIL23R | |
| SCHEMBL29489383 | 0.88 | GLP1R (0.59) | GLP1R | |
| SCHEMBL30973636 | 0.87 | IL23R (0.55) | GLP1RIL23R | |
| SCHEMBL29484313 | 0.82 | NPBWR1 (0.55) | GLP1RIL23R | |
| SCHEMBL30216222 | 0.82 | GLP1R (0.52) | GLP1RIL23R | |
| SCHEMBL30063985 | 0.81 | GLP1R (0.54) | GLP1RIL23R | |
| SCHEMBL30208639 | 0.79 | GLP1R (0.60) | GLP1RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360103-A1 | COMPLEMENT INHIBITION | SIXTH STREET LENDING PARTNERS | 2024-10-31 | — | — | US | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-116829176-A | Complement genome editing | 阿佩利斯制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4213808-A1 | METHODS OF TREATING EYE DISORDERS | Apellis Pharmaceuticals, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023278698-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4087541-A1 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Apellis Pharmaceuticals, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022061304-A1 | METHODS OF TREATING EYE DISORDERS | APELLIS PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360103-A1 | COMPLEMENT INHIBITION | C5, C9, C1QBP | GLP1R 1293/4885IL23R 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.